Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Vedolizumab SC PFS vs Investigational Device in Healthy Subjects
NCT03949621Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vedolizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration, Area Under the Serum Concentration-time Curve From Time 0 to Infinity and 1 more. Started Feb 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03949621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949621.